羧胺三唑乳清酸盐联合替莫唑胺治疗胶质母细胞瘤的IB期试验
结果显示联合治疗耐受良好,未观察到剂量限制性毒性,II期推荐剂量为600 mg/d固定剂量,并在肿瘤和脑组织中达到治疗浓度,同时观察到部分缓解和完全缓解信号。
要点
- CTO联合TMZ或放化疗在胶质母细胞瘤和间变性胶质瘤中耐受良好,未观察到剂量限制性毒性。
- II期推荐剂量为CTO 600 mg/d固定剂量,且CTO不改变TMZ血药浓度。
- 队列1中观察到部分缓解6例和完全缓解1例,包括MGMT未甲基化和贝伐珠单抗难治性肿瘤。
核心结论
- CTO可安全地与TMZ或放化疗联合用于胶质母细胞瘤和间变性胶质瘤,并显示出良好的脑渗透性和有前景的活性信号。
主要发现
- 治疗耐受良好,毒性包括乏力、便秘、恶心和低磷血症。
- 药代动力学显示CTO不改变TMZ水平,在肿瘤和脑组织中达到治疗浓度。
- 未观察到剂量限制性毒性,II期推荐剂量为600 mg/d固定剂量。
- 队列1中部分缓解6例、完全缓解1例,包括O6-甲基鸟嘌呤-DNA甲基转移酶未甲基化和贝伐珠单抗难治性肿瘤。
- 队列2中位无进展生存期为15个月,中位总生存期未达到(中位随访28个月,2年总生存率62%)。
临床怎么用
- CTO联合TMZ或放化疗可作为胶质母细胞瘤和间变性胶质瘤患者的一种耐受性良好的治疗选择,II期推荐剂量为600 mg/d固定剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Carboxyamidotriazole orotate (CTO) is a novel oral inhibitor of non-voltage-dependent calcium channels with modulatory effects in multiple cell-signaling pathways and synergistic effects with temozolomide (TMZ) in glioblastoma (GBM) models. We conducted a phase IB study combining CTO with two standard TMZ schedules in GBM. Methods In cohort 1, patients with recurrent anaplastic gliomas or GBM received escalating doses of CTO (219 to 812.5 mg/m2 once daily or 600 mg fixed once-daily dose) combined with TMZ (150 mg/m2 5 days during each 28-day cycle). In cohort 2, patients with newly diagnosed GBM received escalating doses of CTO (219 to 481 mg/m2/d once daily) with radiotherapy and TMZ 75 mg/m2/d, followed by TMZ 150 mg to 200 mg/m2 5 days during each 28-day cycle. Results Forty-seven patients were enrolled. Treatment was well tolerated; toxicities included fatigue, constipation, nausea, and hypophosphatemia. Pharmacokinetics showed that CTO did not alter TMZ levels; therapeutic concentrations were achieved in tumor and brain. No dose-limiting toxicities were observed; the recommended phase II dose was 600 mg/d flat dose. Signals of activity in cohort 1 (n = 27) included partial (n = 6) and complete (n = 1) response, including in O6-methylguanine-DNA methyltransferase unmethylated and bevacizumab-refractory tumors. In cohort 2 (n = 15), median progression-free survival was 15 months and median overall survival was not reached (median follow-up, 28 months; 2-year overall survival, 62%). Gene sequencing disclosed a high rate of responses among EGFR-amplified tumors ( P = .005), with mechanisms of acquired resistance possibly involving mutations in mismatch-repair genes and/or downstream components TSC2, NF1, NF2, PTEN, and PIK3CA. Conclusion CTO can be combined safely with TMZ or chemoradiation in GBM and anaplastic gliomas, displaying favorable brain penetration and promising signals of activity in this difficult-to-treat population.
引用
- Omuro A, Beal K, McNeill K, et al. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. J Clin Oncol. 2018. PMID: 29683790. doi:10.1200/JCO.2017.76.9992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。